Please confirm you are human (Sign Up for free to never see this)
← Back to Search
A2aR Antagonists: Next Generation Checkpoint Blockade For Cancer Immunotherapy
Robert D Leone, Ying-Chun Lo, J. Powell
Published 2015 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
The last several years have witnessed exciting progress in the development of immunotherapy for the treatment of cancer. This has been due in great part to the development of so-called checkpoint blockade. That is, antibodies that block inhibitory receptors such as CTLA-4 and PD-1 and thus unleash antigen-specific immune responses against tumors. It is clear that tumors evade the immune response by usurping pathways that play a role in negatively regulating normal immune responses. In this regard, adenosine in the immune microenvironment leading to the activation of the A2a receptor has been shown to represent one such negative feedback loop. Indeed, the tumor microenvironment has relatively high concentrations of adenosine. To this end, blocking A2a receptor activation has the potential to markedly enhance anti-tumor immunity in mouse models. This review will present data demonstrating the ability of A2a receptor blockade to enhance tumor vaccines, checkpoint blockade and adoptive T cell therapy. Also, as several recent studies have demonstrated that under certain conditions A2a receptor blockade can enhance tumor progression, we will also explore the complexities of adenosine signaling in the immune response. Despite important nuances to the A2a receptor pathway that require further elucidation, studies to date strongly support the development of A2a receptor antagonists (some of which have already been tested in phase III clinical trials for Parkinson Disease) as novel modalities in the immunotherapy armamentarium.
This paper references
Apparent involvement of the A(2A) subtype adenosine receptor in the anti-inflammatory interactions of CGS 21680, cyclopentyladenosine, and IB-MECA with human neutrophils.
S. S. Visser (2000)
Formation and release of purine catabolites during hypoperfusion, anoxia, and ischemia.
H. van Belle (1987)
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases
G. Haskó (2008)
A2A adenosine receptor protects tumors from antitumor T cells
A. Ohta (2006)
Adenosine receptor subtypes: characterization and therapeutic regulation.
M. E. Olah (1995)
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
H. Kluger (2014)
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
A. Tsao (2012)
The PD‐1 pathway in tolerance and autoimmunity
Loise M. Francisco (2010)
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells.
P. Zarek (2008)
Ecto-ATPase activity in cytolytic T-lymphocytes. Protection from the cytolytic effects of extracellular ATP.
A. Filippini (1990)
Ecto‐enzyme and signaling functions of lymphocyte CD 7 3
R. Resta (1998)
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
P. Waterhouse (1995)
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E. Tivol (1995)
- in fi ltrating CD 8 + T lymphocytes are oligoclonal and PD - 1 +
W Zou (2009)
The expression and clinical significance of CD73 molecule in human rectal adenocarcinoma
B. Zhang (2015)
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
J. Stagg (2010)
Activation of Adenosine 2A Receptors Attenuates Allograft Rejection and Alloantigen Recognition1
Charles P. Sevigny (2007)
Dendritic cells tolerizedwith adenosine A(2)AR agonist attenuate acute kidney injury
L Li (2012)
The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer
B. Henick (2014)
A2B adenosine receptor blockade inhibits growth of prostate cancer cells
Qiang Wei (2012)
Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength.
J. Egen (2002)
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
S. Loi (2013)
Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor.
D. Mittal (2014)
The Roles of CD73 in Cancer
Z. Gao (2014)
CD73-deficient mice are resistant to carcinogenesis.
J. Stagg (2012)
Targeting cancer-derived adenosine: new therapeutic approaches.
A. Young (2014)
CD73-Generated Adenosine: Orchestrating the Tumor-Stroma Interplay to Promote Cancer Growth
B. Allard (2012)
Role of Extracellular ATP and P1 and P2 Classes of Purinergic Receptors in T‐cell Development and Cytotoxic T Lymphocyte Effector Functions
S. Apasov (1995)
Molecular characterization of recombinant human adenosine receptors
A. Robeva (1996)
Historical overview of immunological tolerance.
R. Schwartz (2012)
Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice.
A. Grenz (2017)
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
J. Brahmer (2012)
Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides.
G. Dubyak (1993)
Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model.
R. Iannone (2014)
Adenosine, an endogenous anti-inflammatory agent.
B. Cronstein (1994)
Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease.
M. Odashima (2005)
Immune modulation for cancer therapy
J. Naidoo (2014)
The adenosine a2a receptor inhibits matrix-induced inflammation in a novel fashion.
K. Scheibner (2009)
PD-1 and its ligands in tolerance and immunity.
M. Keir (2008)
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.
P. Armand (2013)
Effects of extracellular ATP and adenosine on different thymocyte subsets: possible role of ATP-gated channels and G protein-coupled purinergic receptor.
S. Apasov (1997)
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
S. Deaglio (2007)
Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor
A. Waickman (2011)
The secret ally: immunostimulation by anticancer drugs
L. Galluzzi (2012)
T-cell regulation by CD28 and CTLA-4
M. Alegre (2001)
Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
Y. Yang (1997)
PD‐1 signaling in primary T cells
J. Riley (2009)
B7-H1 Is Expressed by Human Endothelial Cells and Suppresses T Cell Cytokine Synthesis1
M. M. Mazanet (2002)
Nucleotide signalling during inflammation
M. Idzko (2014)
CTLA-4 is a second receptor for the B cell activation antigen B7
P. Linsley (1991)
Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling.
T. Raskovalova (2007)
Autophagy in non-small cell lung carcinogenesis
S. Rao (2014)
Immunogenic cell death in cancer therapy.
G. Kroemer (2013)
Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 2002;16:23–35
JG Egen (2002)
Adenosine receptors and cancer.
S. Gessi (2011)
A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis.
G. Sullivan (2004)
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
R. Parry (2005)
Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
Y. Ishida (1992)
Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
Caglar Cekic (2014)
Hypoxia-inducible factor-dependent repression of equilibrative nucleoside transporter 2 attenuates mucosal inflammation during intestinal hypoxia.
Julio C. Morote-García (2009)
phoproliferative disorders with early lethality in mice de fi cient in Ctla - 4
P Waterhouse (1995)
Molecular mechanisms of ATP secretion during immunogenic cell death
I. Martins (2014)
The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine.
J. Blay (1997)
CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis.
J. Stagg (2011)
Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis
J. Yang (2007)
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.
J. Westin (2014)
Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
B. Allard (2013)
Adenosine receptors in regulation of dendritic cell differentiation and function.
S. Novitskiy (2008)
Cutting Edge: Critical Role for A2A Adenosine Receptors in the T Cell-Mediated Regulation of Colitis1
M. Naganuma (2006)
Hostile, Hypoxia–A2-Adenosinergic Tumor Biology as the Next Barrier to Overcome for Tumor Immunologists
M. Sitkovsky (2014)
Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors.
H. J. Park (2012)
Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells.
Max Schnurr (2004)
Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued
A. Pinna (2014)
Adenosine A2B Receptor Blockade Slows Growth of Bladder and Breast Tumors
Caglar Cekic (2012)
Purinergic signaling during inflammation.
H. Eltzschig (2012)
CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice.
L. Wang (2011)
Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells.
J. Kim (2005)
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
Computational and Structural Biotechnology Journal
R D Leone (2015)
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
Requirement of NK cells for selective A2A receptor blockade to suppress CD73+ tumor metastasis.
L. Qin (2014)
Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity
T. Curiel (2003)
Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+
K. Sfanos (2009)
Adenosine and anergy
P. Zarek (2007)
Dendritic cells tolerized with adenosine A₂AR agonist attenuate acute kidney injury.
L. Li (2012)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
H. Dong (2002)
Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment.
Caglar Cekic (2014)
Altered purinergic signaling in CD73‐deficient mice inhibits tumor progression
G. Yegutkin (2011)
Human monocytes respond to extracellular cAMP through A2A and A2B adenosine receptors
E. Sciaraffia (2014)
Adenosine-mediated inhibition of cytotoxic activity and cytokine production by IL-2/NKp46-Activated NK cells
T. Raskovalova (2006)
Extracellular adenosine regulates naive T cell development and peripheral maintenance
Caglar Cekic (2013)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
Two novel families of ectonucleotidases: molecular structures, catalytic properties and a search for function.
H. Zimmermann (1999)
Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses
P. Beavis (2015)
Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis
M. Montesinos (2006)
Inhibitory B7-family molecules in the tumour microenvironment
W. Zou (2008)
Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors
Paul A. Beavis (2013)
The A2aR adenosine receptor controls cytokine production in iNKT cells
Michael Nowak (2010)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
H. Dong (2002)
Chemotherapy with immunogenic cell death inducers
E. Vacchelli (2012)
Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage
A. Ohta (2001)
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
CTLA-4 Control over Foxp3+ Regulatory T Cell Function
K. Wing (2008)
Clinical development of the anti-CTLA-4 antibody tremelimumab.
A. Ribas (2010)
This paper is referenced by
A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer
Hsiao-Rong Chen (2016)
Potential Therapeutic Applications of Adenosine A2A Receptor Ligands and Opportunities for A2A Receptor Imaging
A. Waarde (2018)
Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength.
Elena Segala (2016)
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors.
L. Squarcialupi (2016)
Novel Methods to Overcome Acquired Resistance to Immunotherapy
Xianda Zhao (2019)
Immunometabolism of regulatory T cells
Ryan H Newton (2016)
Targeting CD73 in the tumor microenvironment with MEDI9447
C. Hay (2016)
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
P. Beavis (2017)
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Julian A. Marin-Acevedo (2018)
Applying Precision Medicine and Immunotherapy Advances from Oncology to Host-Directed Therapies for Infectious Diseases
R. Mahon (2017)
Immune Checkpoint Inhibitors to Treat Malignant Lymphomas
M. Witkowska (2018)
Ebola virus: entry, pathogenesis and identification of host antiviral activities
Bethany A. Rhein (2015)
Small-Molecule Targets in Immuno-Oncology.
D. Dhanak (2017)
Analysis of Vipadenant and Its In Vitro and In Vivo Metabolites via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry
Seok-Ho Shin (2018)
Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non‐MSI‐H Metastatic Colorectal Cancer
J. Lee (2018)
A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models
S. Willingham (2018)
Drug discovery: Standing on the shoulders of giants
S. Miller (2017)
Novel Checkpoints and Cosignaling Molecules in Cancer Immunotherapy
I. Giuroiu (2017)
Risk of cancer after an acute coronary syndrome according to the type of P2Y12 inhibitor.
S. Raposeiras-Roubín (2019)
Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity
A. Glukhova (2017)
Adenosine A2A Receptor Stimulation Inhibits TCR-Induced Notch1 Activation in CD8+T-Cells
C. Sorrentino (2019)
Targeting adenosine A2A receptor antagonism for treatment of cancer
M. Congreve (2018)
Immune checkpoint blockade for hematologic malignancies: a review.
Matthew J Pianko (2017)
Association d'un modulateur de points de contrôle immunologiques et d'un complexe comprenant un peptide de pénétration cellulaire, un cargo et un agoniste des peptides tlr pour une utilisation en médecine
Madiha Derouazi (2017)
A cell-engineered system to assess tumor cell sensitivity to CD8+ T cell-mediated cytotoxicity
Nadine Nelson (2019)
Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer
Y. Inoue (2017)
G Protein‐Coupled receptors and heterotrimeric G proteins as cancer drivers
Nadia Arang (2020)
T lymphocyte-targeted immune checkpoint modulation in glioma
W. Kelly (2020)
Modulation of dendritic cell and T cell cross-talk during aging: The potential role of checkpoint inhibitory molecules
Joanne K Gardner (2017)
Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3)
V. Homayouni (2016)
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Wendy Mao (2019)
Notch Signaling in Embryology and Cancer: Notch Signaling in Cancer
J. Reichrath (2021)See more